Glaxosmithkline Pharma Q1 consolidated net profit up 8% at Rs 116 crore

Drug manufacturers GlaxoSmithKline on Monday said its consolidated net profit increased to Rs 116 crore in the first quarter. Shares of the company closed at Rs 1,726.20 on BSE, said reports

GlaxoSmithKline, gsk
GSK
Press Trust of India New Delhi
1 min read Last Updated : Jul 25 2022 | 10:59 PM IST

GlaxoSmithKline Pharmaceuticals on Monday said its consolidated net profit increased by 8 per cent to Rs 116 crore in the first quarter ended on June 30, 2022.

The drug firm had reported a net profit of Rs 107 crore in the April-June quarter of the previous year.

Revenue from operations rose to Rs 745 crore as against Rs 718 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing.

"Our results reflect good momentum across general medicines and vaccines during the quarter. We have delivered strong underlying growth with market share gains across focus brands," GlaxoSmithKline Pharmaceuticals MD Sridhar Venkatesh noted.

The drug firm is a subsidiary of GSK plc, a global biopharma company.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :GlaxoSmithKlineGlaxoSmithKline PharmaceuticalsDrug makers in India

First Published: Jul 25 2022 | 8:10 PM IST

Next Story